Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Correction to: Delta Opioid Receptor Pharmacology and Therapeutic Applications.

Jutkiewicz EM.

Handb Exp Pharmacol. 2018;247:C1-C2. doi: 10.1007/978-3-319-95133-1_1001.

PMID:
31309359
2.

Correction to: The protein kinase Cβ-selective inhibitor, enzastaurin, attenuates amphetamine-stimulated locomotor activity and self-administration behaviors in rats.

Altshuler RD, Carpenter CA, Franke TJ, Gnegy ME, Jutkiewicz EM.

Psychopharmacology (Berl). 2019 Jul 3. doi: 10.1007/s00213-019-05312-1. [Epub ahead of print]

PMID:
31270556
3.

The protein kinase Cβ-selective inhibitor, enzastaurin, attenuates amphetamine-stimulated locomotor activity and self-administration behaviors in rats.

Altshuler RD, Carpenter CA, Franke TJ, Gnegy ME, Jutkiewicz EM.

Psychopharmacology (Berl). 2019 May 27. doi: 10.1007/s00213-019-05278-0. [Epub ahead of print] Erratum in: Psychopharmacology (Berl). 2019 Jul 3;:.

PMID:
31134292
4.

Effects of adolescent Δ9-tetrahydrocannabinol exposure on the behavioral effects of cocaine in adult Sprague-Dawley rats.

Friedman AL, Meurice C, Jutkiewicz EM.

Exp Clin Psychopharmacol. 2019 Apr 1. doi: 10.1037/pha0000276. [Epub ahead of print]

PMID:
30932503
5.

Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.

Nastase AF, Anand JP, Bender AM, Montgomery D, Griggs NW, Fernandez TJ, Jutkiewicz EM, Traynor JR, Mosberg HI.

J Med Chem. 2019 Apr 25;62(8):4193-4203. doi: 10.1021/acs.jmedchem.9b00378. Epub 2019 Apr 9.

PMID:
30916966
6.

Role of hippocampal 5-HT1A receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive Gαi2 protein.

Senese NB, Oginsky M, Neubig RR, Ferrario C, Jutkiewicz EM, Traynor JR.

Neuropharmacology. 2018 Oct;141:296-304. doi: 10.1016/j.neuropharm.2018.09.002. Epub 2018 Sep 4.

PMID:
30189184
7.

Tolerance to high-internalizing δ opioid receptor agonist is critically mediated by arrestin 2.

Vicente-Sanchez A, Dripps IJ, Tipton AF, Akbari H, Akbari A, Jutkiewicz EM, Pradhan AA.

Br J Pharmacol. 2018 Jul;175(14):3050-3059. doi: 10.1111/bph.14353. Epub 2018 Jun 7.

8.

Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.

Nastase AF, Griggs NW, Anand JP, Fernandez TJ, Harland AA, Trask TJ, Jutkiewicz EM, Traynor JR, Mosberg HI.

ACS Chem Neurosci. 2018 Jul 18;9(7):1840-1848. doi: 10.1021/acschemneuro.8b00139. Epub 2018 May 2.

PMID:
29677442
9.

In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.

Anand JP, Kochan KE, Nastase AF, Montgomery D, Griggs NW, Traynor JR, Mosberg HI, Jutkiewicz EM.

Br J Pharmacol. 2018 Jun;175(11):2013-2027. doi: 10.1111/bph.14148. Epub 2018 Apr 24.

10.

Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80.

Dripps IJ, Boyer BT, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM.

Br J Pharmacol. 2018 Mar;175(6):891-901. doi: 10.1111/bph.14131. Epub 2018 Feb 9.

11.

Cocaine and desipramine elicit distinct striatal noradrenergic and behavioral responses in selectively bred obesity-resistant and obesity-prone rats.

Vollbrecht PJ, Nesbitt KM, Mabrouk OS, Chadderdon AM, Jutkiewicz EM, Kennedy RT, Ferrario CR.

Behav Brain Res. 2018 Jul 2;346:137-143. doi: 10.1016/j.bbr.2017.11.009. Epub 2017 Nov 9.

12.

Delta Opioid Receptors and Modulation of Mood and Emotion.

Dripps IJ, Jutkiewicz EM.

Handb Exp Pharmacol. 2018;247:179-197. doi: 10.1007/164_2017_42. Review.

PMID:
28993835
13.

Role of the guanine nucleotide binding protein, Gαo, in the development of morphine tolerance and dependence.

Lamberts JT, Rosenthal LD, Jutkiewicz EM, Traynor JR.

Psychopharmacology (Berl). 2018 Jan;235(1):71-82. doi: 10.1007/s00213-017-4742-2. Epub 2017 Oct 3.

14.

Design, synthesis, and biological activity of 5'-phenyl-1,2,5,6-tetrahydro-3,3'-bipyridine analogues as potential antagonists of nicotinic acetylcholine receptors.

Jin Y, Huang X, Papke RL, Jutkiewicz EM, Showalter HD, Zhan CG.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4350-4353. doi: 10.1016/j.bmcl.2017.08.025. Epub 2017 Aug 14.

15.

Multiple DSM-5 substance use disorders: A national study of US adults.

McCabe SE, West BT, Jutkiewicz EM, Boyd CJ.

Hum Psychopharmacol. 2017 Sep;32(5). doi: 10.1002/hup.2625. Epub 2017 Jul 27.

16.

The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Dripps IJ, Wang Q, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM.

Psychopharmacology (Berl). 2017 Jan;234(1):29-39. doi: 10.1007/s00213-016-4432-5. Epub 2016 Sep 13.

17.

Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands.

Harland AA, Bender AM, Griggs NW, Gao C, Anand JP, Pogozheva ID, Traynor JR, Jutkiewicz EM, Mosberg HI.

J Med Chem. 2016 May 26;59(10):4985-98. doi: 10.1021/acs.jmedchem.6b00308. Epub 2016 May 16.

18.

The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.

Anand JP, Boyer BT, Mosberg HI, Jutkiewicz EM.

Psychopharmacology (Berl). 2016 Jul;233(13):2479-87. doi: 10.1007/s00213-016-4296-8. Epub 2016 Apr 27.

19.

Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.

Harland AA, Yeomans L, Griggs NW, Anand JP, Pogozheva ID, Jutkiewicz EM, Traynor JR, Mosberg HI.

J Med Chem. 2015 Nov 25;58(22):8952-69. doi: 10.1021/acs.jmedchem.5b01270. Epub 2015 Nov 13.

20.

Pre-existing differences in motivation for food and sensitivity to cocaine-induced locomotion in obesity-prone rats.

Vollbrecht PJ, Nobile CW, Chadderdon AM, Jutkiewicz EM, Ferrario CR.

Physiol Behav. 2015 Dec 1;152(Pt A):151-60. doi: 10.1016/j.physbeh.2015.09.022. Epub 2015 Sep 28.

21.

Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.

Bender AM, Griggs NW, Anand JP, Traynor JR, Jutkiewicz EM, Mosberg HI.

ACS Chem Neurosci. 2015 Aug 19;6(8):1428-35. doi: 10.1021/acschemneuro.5b00100. Epub 2015 May 13.

22.

Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors.

Blazer LL, Storaska AJ, Jutkiewicz EM, Turner EM, Calcagno M, Wade SM, Wang Q, Huang XP, Traynor JR, Husbands SM, Morari M, Neubig RR.

ACS Chem Neurosci. 2015 Jun 17;6(6):911-9. doi: 10.1021/acschemneuro.5b00063. Epub 2015 Apr 20.

PMID:
25844489
23.

Preoperative ultra-rapid opiate detoxification for the treatment of post-operative surgical pain.

Blum JM, Biel SS, Hilliard PE, Jutkiewicz EM.

Med Hypotheses. 2015 Jun;84(6):529-31. doi: 10.1016/j.mehy.2015.02.008. Epub 2015 Mar 6.

PMID:
25816931
24.

Single prolonged stress effects on sensitization to cocaine and cocaine self-administration in rats.

Eagle AL, Singh R, Kohler RJ, Friedman AL, Liebowitz CP, Galloway MP, Enman NM, Jutkiewicz EM, Perrine SA.

Behav Brain Res. 2015 May 1;284:218-24. doi: 10.1016/j.bbr.2015.02.027. Epub 2015 Feb 21.

25.

Automated touch screen device for recording complex rodent behaviors.

Mabrouk OS, Dripps IJ, Ramani S, Chang C, Han JL, Rice KC, Jutkiewicz EM.

J Neurosci Methods. 2014 Aug 15;233:129-36. doi: 10.1016/j.jneumeth.2014.05.004. Epub 2014 Jun 19.

26.

Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance.

Mosberg HI, Yeomans L, Anand JP, Porter V, Sobczyk-Kojiro K, Traynor JR, Jutkiewicz EM.

J Med Chem. 2014 Apr 10;57(7):3148-53. doi: 10.1021/jm5002088. Epub 2014 Mar 26.

27.

Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism.

Bosse KE, Jutkiewicz EM, Schultz-Kuszak KN, Mabrouk OS, Kennedy RT, Gnegy ME, Traynor JR.

Neuropharmacology. 2014 Feb;77:19-27. doi: 10.1016/j.neuropharm.2013.08.027. Epub 2013 Sep 10.

28.

Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.

Mosberg HI, Yeomans L, Harland AA, Bender AM, Sobczyk-Kojiro K, Anand JP, Clark MJ, Jutkiewicz EM, Traynor JR.

J Med Chem. 2013 Mar 14;56(5):2139-49. doi: 10.1021/jm400050y. Epub 2013 Feb 27.

29.

Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.

Jutkiewicz EM, Rice KC, Carroll FI, Woods JH.

Drug Alcohol Depend. 2013 Aug 1;131(3):284-97. doi: 10.1016/j.drugalcdep.2012.12.021. Epub 2013 Jan 18.

30.

Endogenous opioids as physiological antidepressants: complementary role of δ receptors and dopamine.

Jutkiewicz EM, Roques BP.

Neuropsychopharmacology. 2012 Jan;37(1):303-4. doi: 10.1038/npp.2011.244. No abstract available.

31.

5-Hydroxytryptophan attenuates somatic signs of nicotine withdrawal.

Ohmura Y, Jutkiewicz EM, Yoshioka M, Domino EF.

J Pharmacol Sci. 2011;117(2):121-4.

32.

Patterns of nicotinic receptor antagonism: nicotine discrimination studies.

Jutkiewicz EM, Brooks EA, Kynaston AD, Rice KC, Woods JH.

J Pharmacol Exp Ther. 2011 Oct;339(1):194-202. doi: 10.1124/jpet.111.182170. Epub 2011 Jul 5.

33.

μ-Opioid receptor coupling to Gα(o) plays an important role in opioid antinociception.

Lamberts JT, Jutkiewicz EM, Mortensen RM, Traynor JR.

Neuropsychopharmacology. 2011 Sep;36(10):2041-53. doi: 10.1038/npp.2011.91. Epub 2011 Jun 8.

34.

Dopamine D1/5 and D2/3 agonists differentially attenuate somatic signs of nicotine withdrawal in rats.

Ohmura Y, Jutkiewicz EM, Zhang A, Domino EF.

Pharmacol Biochem Behav. 2011 Oct;99(4):552-6. doi: 10.1016/j.pbb.2011.05.010. Epub 2011 May 23.

PMID:
21624384
35.

L-DOPA attenuates nicotine withdrawal-induced behaviors in rats.

Ohmura Y, Jutkiewicz EM, Domino EF.

Pharmacol Biochem Behav. 2011 Jun;98(4):552-8. doi: 10.1016/j.pbb.2011.02.007. Epub 2011 Feb 24.

PMID:
21354201
36.
37.

RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.

Talbot JN, Jutkiewicz EM, Graves SM, Clemans CF, Nicol MR, Mortensen RM, Huang X, Neubig RR, Traynor JR.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11086-91. doi: 10.1073/pnas.1000003107. Epub 2010 Jun 2.

38.

Conditional ablation and recovery of forebrain neurogenesis in the mouse.

Singer BH, Jutkiewicz EM, Fuller CL, Lichtenwalner RJ, Zhang H, Velander AJ, Li X, Gnegy ME, Burant CF, Parent JM.

J Comp Neurol. 2009 Jun 20;514(6):567-82. doi: 10.1002/cne.22052.

39.

A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality.

Jutkiewicz EM, Baladi MG, Cooper ZD, Narasimhan D, Sunahara RK, Woods JH.

Ann Emerg Med. 2009 Sep;54(3):409-20. doi: 10.1016/j.annemergmed.2008.09.023. Epub 2008 Nov 14.

40.

The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum.

Bosse KE, Jutkiewicz EM, Gnegy ME, Traynor JR.

Neuropharmacology. 2008 Oct;55(5):755-62. doi: 10.1016/j.neuropharm.2008.06.017. Epub 2008 Jun 18.

41.

Nicotine and amphetamine acutely cross-potentiate their behavioral and neurochemical responses in female Holtzman rats.

Jutkiewicz EM, Nicolazzo DM, Kim MN, Gnegy ME.

Psychopharmacology (Berl). 2008 Sep;200(1):93-103. doi: 10.1007/s00213-008-1159-y. Epub 2008 Jun 20.

PMID:
18566803
43.

RB101-mediated protection of endogenous opioids: potential therapeutic utility?

Jutkiewicz EM.

CNS Drug Rev. 2007 Summer;13(2):192-205. Review.

44.

Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase.

Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, Wilson IA, Landry DW, Woods JH.

Mol Pharmacol. 2006 Dec;70(6):1885-91. Epub 2006 Sep 12.

PMID:
16968810
45.

The antidepressant -like effects of delta-opioid receptor agonists.

Jutkiewicz EM.

Mol Interv. 2006 Jun;6(3):162-9. Review.

PMID:
16809477
46.

The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol.

Jutkiewicz EM, Baladi MG, Folk JE, Rice KC, Woods JH.

J Pharmacol Exp Ther. 2006 Jun;317(3):1337-48. Epub 2006 Mar 14.

PMID:
16537798
47.

Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects.

Zhang H, Torregrossa MM, Jutkiewicz EM, Shi YG, Rice KC, Woods JH, Watson SJ, Ko MC.

Eur J Neurosci. 2006 Feb;23(4):984-94.

48.

Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.

Jutkiewicz EM, Torregrossa MM, Sobczyk-Kojiro K, Mosberg HI, Folk JE, Rice KC, Watson SJ, Woods JH.

Eur J Pharmacol. 2006 Feb 15;531(1-3):151-9. Epub 2006 Jan 25.

49.

Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.

Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH.

Brain Res. 2006 Jan 19;1069(1):172-81. Epub 2005 Dec 20.

50.

Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats.

Jutkiewicz EM, Rice KC, Traynor JR, Woods JH.

Psychopharmacology (Berl). 2005 Nov;182(4):588-96. Epub 2005 Oct 19.

Supplemental Content

Loading ...
Support Center